28483455|t|Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP1 receptor antagonists
28483455|a|Herein we described the design, synthesis and evaluation of a novel series of benzo[d]thiazole derivatives toward an orally active EP1 antagonist. Lead generation studies provided benzo[d]thiazole core from the four designed scaffolds. Optimization of this scaffold in terms of EP1 antagonist potency and ligand-lipophilicity efficiency (LLE; pIC50-clogP) led to a 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazole derivative, 7r (IC50 1.1nM; LLE 4.7), which showed a good pharmacological effect when administered intraduodenally in a 17-phenyl trinor-PGE2 (17-PTP)- induced overactive bladder model in rats.
28483455	0	14	Identification	T052	C0441655
28483455	24	79	1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles	T121	C1254351
28483455	81	96	Lead generation	T062	C0242481
28483455	101	113	optimization	T052	C2698650
28483455	132	138	orally	T169	C1527415
28483455	139	145	active	T169	C0205177
28483455	146	158	EP1 receptor	T116,T192	C2936364
28483455	159	170	antagonists	T044	C1373004
28483455	195	201	design	T052	C1707689
28483455	203	212	synthesis	T070	C0007987
28483455	217	227	evaluation	T078	C1550157
28483455	249	277	benzo[d]thiazole derivatives	T121	C1254351
28483455	288	294	orally	T169	C1527415
28483455	295	301	active	T169	C0205177
28483455	302	305	EP1	T116,T192	C2936364
28483455	306	316	antagonist	T044	C1373004
28483455	318	341	Lead generation studies	T062	C0242481
28483455	351	372	benzo[d]thiazole core	T104	C1254350
28483455	396	405	scaffolds	T079	C1254367
28483455	407	419	Optimization	T052	C2698650
28483455	428	436	scaffold	T079	C1254367
28483455	449	452	EP1	T116,T192	C2936364
28483455	453	463	antagonist	T044	C1373004
28483455	464	471	potency	T038	C0678792
28483455	476	507	ligand-lipophilicity efficiency	T081	C0013682
28483455	509	512	LLE	T081	C0013682
28483455	514	525	pIC50-clogP	T081	C0392762
28483455	536	605	1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazole derivative, 7r	T121	C1254351
28483455	607	611	IC50	T081	C0600495
28483455	619	622	LLE	T081	C0013682
28483455	649	664	pharmacological	T169	C0205464
28483455	665	671	effect	T080	C1280500
28483455	677	689	administered	T169	C1521801
28483455	690	705	intraduodenally	T169	C1512937
28483455	711	732	17-phenyl trinor-PGE2	T109	C0295046
28483455	734	740	17-PTP	T109	C0295046
28483455	743	750	induced	T169	C0205263
28483455	751	769	overactive bladder	T047	C0878773
28483455	770	775	model	T075	C0026336
28483455	779	783	rats	T015	C0034693